Medtronic PLC (NYSE:MDT) – Analysts at Leerink Swann lifted their FY2018 earnings per share estimates for shares of Medtronic in a research report issued on Wednesday. Leerink Swann analyst D. Antalffy now anticipates that the medical technology company will post earnings per share of $4.81 for the year, up from their previous forecast of $4.80. Leerink Swann has a “Market Perform” rating and a $85.00 price target on the stock. Leerink Swann also issued estimates for Medtronic’s FY2019 earnings at $5.15 EPS, FY2020 earnings at $5.52 EPS and FY2021 earnings at $5.93 EPS.

A number of other research analysts have also recently weighed in on MDT. Jefferies Group reiterated a “buy” rating and issued a $103.00 target price on shares of Medtronic in a research note on Thursday, August 3rd. BidaskClub cut shares of Medtronic from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Royal Bank Of Canada restated a “buy” rating and set a $90.00 price target on shares of Medtronic in a research note on Monday, August 21st. Oppenheimer restated a “buy” rating and set a $92.00 price target on shares of Medtronic in a research note on Tuesday, August 22nd. Finally, Cowen set a $95.00 price target on shares of Medtronic and gave the company a “buy” rating in a research note on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $88.02.

Medtronic (MDT) traded down $0.86 on Friday, reaching $81.27. 5,993,062 shares of the company’s stock were exchanged, compared to its average volume of 4,941,329. The company has a current ratio of 2.40, a quick ratio of 2.05 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $111,170.00, a PE ratio of 17.77, a price-to-earnings-growth ratio of 2.28 and a beta of 1.00. Medtronic has a 52-week low of $69.35 and a 52-week high of $89.72.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.08. The firm had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The company’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 earnings per share.

A number of institutional investors have recently bought and sold shares of the stock. Glassman Wealth Services increased its holdings in shares of Medtronic by 20.1% in the 1st quarter. Glassman Wealth Services now owns 2,593 shares of the medical technology company’s stock worth $209,000 after buying an additional 434 shares during the last quarter. Boston Private Wealth LLC grew its holdings in shares of Medtronic by 0.9% during the 1st quarter. Boston Private Wealth LLC now owns 362,338 shares of the medical technology company’s stock valued at $29,190,000 after purchasing an additional 3,390 shares during the last quarter. Motley Fool Wealth Management LLC grew its holdings in shares of Medtronic by 42.1% during the 1st quarter. Motley Fool Wealth Management LLC now owns 140,564 shares of the medical technology company’s stock valued at $11,324,000 after purchasing an additional 41,654 shares during the last quarter. BB&T Securities LLC grew its holdings in shares of Medtronic by 24.9% during the 1st quarter. BB&T Securities LLC now owns 211,029 shares of the medical technology company’s stock valued at $16,999,000 after purchasing an additional 42,112 shares during the last quarter. Finally, River & Mercantile Asset Management LLP grew its holdings in shares of Medtronic by 5.4% during the 1st quarter. River & Mercantile Asset Management LLP now owns 32,050 shares of the medical technology company’s stock valued at $2,582,000 after purchasing an additional 1,650 shares during the last quarter. 81.78% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.02, for a total transaction of $1,264,320.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the sale, the chief executive officer now directly owns 668,503 shares in the company, valued at approximately $54,569,899.89. The disclosure for this sale can be found here. Insiders have sold a total of 172,407 shares of company stock worth $13,974,223 in the last ninety days. 0.31% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/medtronic-plc-mdt-forecasted-to-earn-fy2018-earnings-of-4-81-per-share.html.

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Earnings History and Estimates for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.